micro-community-banner
 
  • Saved

2yr
Modifying Antibody-FcRn Interactions to Increase the Transport of Antibodies Through the Blood-Brain Barrier

Modifying Antibody-FcRn Interactions to Increase the Transport of Antibodies Through the Blood-Brain Barrier

Source : https://pubmed.ncbi.nlm.nih.gov/37381177/

The blood-brain barrier (BBB) largely excludes antibodies from entering the central nervous system, thus limiting the potential of therapeutic antibodies to treat conditions such as neurodegenerative diseases and neuro-psychiatric disorders.

Several Fc mutations, such as certain substitutions found on efgartigimod, enhance antibody-FcRn interactions in low and high pH environments. The researchers propose that site-directed mutagenesis along the Fc-FcRn interface to search for mutations that enhance antibody-FcRn interactions in a pH-independent manner may identify substitutions...

  • Saved

2yr
Propofol TCI or Sevoflurane Anesthesia Without Muscle Relaxant for Thoracoscopic Thymectomy in Myasthenia Gravis Patients: a Prospective, Observational Study

Propofol TCI or Sevoflurane Anesthesia Without Muscle Relaxant for Thoracoscopic Thymectomy in Myasthenia Gravis Patients: a Prospective, Observational Study

Source : https://bmcanesthesiol.biomedcentral.com/articles/10.1186/s12871-023-02296-6

Myasthenia gravis (MG) patients interact unpredictably with anesthetic agents, including neuromuscular blocking agents. Here, we investigate the effectiveness of general anesthesia without muscle relaxants using either propofol via target-controlled infusion...

Anesthesia with propofol TCI or sevoflurane without muscle relaxants in patients with MG offered good intraoperative and postoperative conditions for thoracoscopic thymectomy.

  • Saved

2yr
Preview of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) 2023 Annual Meeting

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) will host its annual meeting from Nov. 1 to 4, 2023, at the JW Marriott Desert Ridge in Phoenix.

Physicians, technologists, advanced practice providers, and other health care providers will gather to learn about the latest in neuromuscular, musculoskeletal, and electrodiagnostic medicine and neuromuscular ultrasound. 

We will be covering the event for you, so check your email for highlights and a wrap-up of the conference.

Click above for an exclusive preview of the event.

  • Saved

2yr
Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: a Systematic Review and Meta-Analysis

Clinical Characteristics Associated With Secondary Generalization in Patients With Ocular Myasthenia Gravis: a Systematic Review and Meta-Analysis

Source : https://n.neurology.org/content/101/16/e1594

Background and Objectives Ocular myasthenia gravis (OMG) is an autoimmune disorder resulting in ocular symptoms such as diplopia and ptosis. The proportion of patients who convert to secondary generalized myasthenia...

Risk factors such as female sex and anti-AChR positivity have been identified to have possible associations with SGMG, but there are not enough quality observational studies. There is a need for a prospective global database of patients with OMG, including all countries with different populations.

  • Saved

2yr
Effect of efgartigimod on Muscle Group Subdomains in Participants With Generalized Myasthenia Gravis: Post Hoc Analyses of the Phase 3 Pivotal ADAPT Study

Effect of efgartigimod on Muscle Group Subdomains in Participants With Generalized Myasthenia Gravis: Post Hoc Analyses of the Phase 3 Pivotal ADAPT Study

Source : https://pubmed.ncbi.nlm.nih.gov/37843174/

These post hoc analyses of MG-ADL and QMG subdomain data from ADAPT suggest that efgartigimod is beneficial in improving muscle function and strength across all muscle groups, leading to the...

These findings confirm that efgartigimod can improve function and strength across all muscle groups involved in the symptomatology of gMG, with potential implications in reducing disease burden in patients affected by weakness in these subdomains. The data also support the benefit efgartigimod offers across MG-ADL and QMG subdomains and in a...